الانتقال إلى المحتوى الرئيسي
xMedica

NCT06605404ClinicalTrials.gov

Pan-tumor MRD Study

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to…

رصديةمطلوب 1,350 مشاركاً47 موقعاًدولة واحدة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2024-09-20; recorded start 2025-01-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Paradigm Health)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 7 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,350 participants (target), run at 47 sites.

How this score is built
  • Enrolment31/40

    1,350 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 88 months

  • Sponsor scale0/10

    Paradigm Health has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

الحالات

  • Muscle Invasive Bladder Urothelial Carcinoma
  • Esophageal Cancer
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Melanoma (Skin Cancer)
  • NSCLC (Non-small Cell Lung Cancer)
  • Pancreatic (Exocrine Only)
  • Mix of Solid Tumors (MOST)

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا
طريقة أخذ العيناتNON_PROBABILITY_SAMPLE

مجتمع الدراسة

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

الأهلية كما كُتبت في السجل

Eligibility Criteria: 1. Age 18 years or older. 2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1). 3. Eligible for curative intent therapy, with surgical resection of cancer planned. a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2. 5. No systemic therapy for current cancer diagnosis administered before enrollment. 6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision. 7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required). 8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers. 9. No prior allogeneic hematopoietic stem cell transplant. 10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information. Cohort Specific Criteria 11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer: 12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer. 13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease. 14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts. The following tumor types are excluded: 1. Central nervous system (CNS) malignancies 2. Colorectal cancer 3. Breast cancer 4. Squamous cell skin cancer 5. Basal cell carcinoma 6. Gastrointestinal stromal tumors (GIST) 7. Thyroid cancer 8. Uveal melanoma 9. Low or intermediate grade neuroendocrine tumors ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible 10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةرصدية
المرحلةغير مذكور في سجل السجل
التخصيصغير مذكور في سجل السجل
نموذج التدخّلغير مذكور في سجل السجل
الغرض الأساسيغير مذكور في سجل السجل
التعميةغير مذكور في سجل السجل
التجنيدمطلوب 1,350 مشاركاً

الجهة الراعية والمتعاونون

  • Paradigm Health الجهة الراعية

الأذرع والتدخلات

  • Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

    Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

  • Esophageal

    Esophageal cancer

  • Gastric and Gastroesophageal Junction (GEJ)

    Gastric and Gastroesophageal Junction (GEJ)

  • Melanoma

    Melanoma

  • Non-small cell lung (NSCLC)

    Non-small cell lung (NSCLC)

  • Pancreatic (exocrine only)

    Pancreatic (exocrine only)

  • Mix of Solid Tumors (MOST)

    Mix of Solid Tumors (MOST)

التدخلات

  • اختبار تشخيصي blood and tissue samples

    routine standard of care

  • أخرى blood and tissue samples

    Routine standard of care

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Blood and tissue biospecimen registry

    To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

    الإطار الزمني Observation from enrollment to 5.5 years after enrollment

التواريخ

التواريخ
تاريخ البدء8 يناير 2025 (فعلي)
الإتمام الأولي1 ديسمبر 2031 (تقديري)
الإتمام1 أبريل 2032 (تقديري)
أول نشر20 سبتمبر 2024 (فعلي)
آخر تحديث24 سبتمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةسبتمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

47 موقعاً قيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Piedmont Cancer InstituteAtlantaGeorgiaقيد التجنيد
Guthrie Lourdes Memorial Hospital (GLMH)BinghamtonNew Yorkقيد التجنيد
Alabama OncologyBirminghamAlabamaقيد التجنيد
Mohtaseb Cancer Center and Blood DisordersBullhead CityArizonaقيد التجنيد
Gabrail Cancer CenterCantonOhioقيد التجنيد
Cancer & Blood Specialists of ArizonaCasa GrandeArizonaقيد التجنيد
Carolina Oncology SpecialistsCharlotteNorth Carolinaقيد التجنيد
Oncology & Hematology Associates of West BrowardCoral SpringsFloridaقيد التجنيد
Baptist Health CorbinCorbinKentuckyقيد التجنيد
Pontchartrain Cancer CenterCovingtonLouisianaقيد التجنيد
Baptist Health HardinElizabethtownKentuckyقيد التجنيد
The Melanoma and Skin Cancer InstituteEnglewoodColoradoقيد التجنيد
San Juan Oncology AssociatesFarmingtonNew Mexicoقيد التجنيد
Los Angeles Cancer Network (LACN)GlendaleCaliforniaقيد التجنيد
Southeastern Medical Oncology Center (SMOC)GoldsboroNorth Carolinaقيد التجنيد
The Cancer & Hematology Centers (CHC)Grand RapidsMichiganقيد التجنيد
Onocology Consultants P.A. (Oncology Consultants [OC Houston])HoustonTexasقيد التجنيد
Community Clinical TrialsKingwoodTexasقيد التجنيد
Lancaster General Hospital (UPenn)LancasterPennsylvaniaقيد التجنيد
Baptist Health LexingtonLexingtonKentuckyقيد التجنيد
Cancer Partners of NebraskaLincolnNebraskaقيد التجنيد
CARTILittle RockArkansasقيد التجنيد
Baptist Health LouisvilleLouisvilleKentuckyقيد التجنيد
Taylor Cancer Research CenterMaumeeOhioقيد التجنيد
Cancer Care Specialists of Illinois (CCSI)O'FallonIllinoisقيد التجنيد
Mid Florida Cancer CentersOrange CityFloridaقيد التجنيد
Ventura County Hematology Oncology SpecialistsOxnardCaliforniaقيد التجنيد
Oregon Health & Science University (OHSU)PortlandOregonقيد التجنيد
Virginia Cancer InstituteRichmondVirginiaقيد التجنيد
Mayo ClinicRochesterMinnesotaقيد التجنيد
Medical Oncology Associates of San Diego (MOASD)San DiegoCaliforniaقيد التجنيد
Medical Oncology Associates of San DiegoSan DiegoCaliforniaقيد التجنيد
Guthrie FoundationSayrePennsylvaniaقيد التجنيد
New York Cancer & Blood SpecialistsShirleyNew Yorkقيد التجنيد
Christus Health HighlandsShreveportLouisianaقيد التجنيد
Highlands Oncology Group (HOG)SpringdaleArkansasقيد التجنيد
Cox HealthSpringfieldMissouriقيد التجنيد
Comprehensive Hematology Oncology (CHO)St. PetersburgFloridaقيد التجنيد
Stockton Hematology Oncology Med GroupStocktonCaliforniaقيد التجنيد
Northwest Medical Specialties (NWMS)TacomaWashingtonقيد التجنيد
Christus St. Michael'sTexarkanaTexasقيد التجنيد
Cotton O'Neil Cancer Center [Stormont Vail]TopekaKansasقيد التجنيد
Oklahoma Cancer Specialists and Research Institute (OCSRI)TulsaOklahomaقيد التجنيد
Carle HealthUrbanaIllinoisقيد التجنيد
Cancer Center of KansasWichitaKansasقيد التجنيد
Regional Medical Oncology CenterWilsonNorth Carolinaقيد التجنيد
Cancer Care Associates of York (CCAY)YorkPennsylvaniaقيد التجنيد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 24 سبتمبر 2026

    أُضيف موقع

    45 sites added (47 total)

    247